> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-67/
- Published: 2022-02-06T12:00:00.000Z
- Updated: 2026-09-14T17:31:27.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5151040

**Comments Extended on Device Modeling/Simulation Guide**  
2/4/2022 *Federal Register* notice: FDA is extending the comment period for a 12/23 notice on a draft guidance entitled “Assessing the Credibility of Computational Modeling and Simulation in Medical Device Submissions.” Comments should now be submitted by 3/4\. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-01-28/pdf/2022-01788.pdf?ref=fdaweb.com).

**Info Collection on FDA Communications Testing**  
2/3/2022 *Federal Register* notice: FDA has submitted to OMB an information collection extension entitled “Generic Clearance for Quantitative Testing for the Development of FDA Communications” (OMB Control Number 0910-0865). The collection covers FDA’s use of quantitative social/behavioral science data collection techniques (i.e., surveys and experimental studies) to test consumers’ reactions to FDA communications or educational messaging about FDA-regulated food and cosmetic products, dietary supplements, and animal food and feed. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-01-28/pdf/2022-01730.pdf?ref=fdaweb.com).

**Device Export Foreign Approval Letters Info Collection**  
2/3/2022 *Federal Register* notice: FDA is seeking comments on an information collection extension entitled “Export of Medical Devices; Foreign Letters of Approval” (OMB Control Number 0910-0264). Section 801(e)(2) of the Federal Food, Drug, and Cosmetic Act provides for the exportation of an unapproved device under certain circumstances. The agency requires written authorization from the appropriate office within the foreign government approving the device importation. An alternative to obtaining written authorization from the foreign government is to accept a notarized certification from the responsible company that the product is not in conflict with the foreign country’s laws. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-01-28/pdf/2022-01793.pdf?ref=fdaweb.com).

**Final Guidance on Good ANDA Submission**  
2/2/2022 *Federal Register* notice: FDA has made available a final guidance entitled “Good ANDA Submission Practices.” The document highlights common, recurring deficiencies that may lead to an ANDA approval delay. It also makes recommendations to applicants on how to avoid the deficiencies and minimize the number of review cycles. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-01-27/pdf/2022-01580.pdf?ref=fdaweb.com).

**Guide on Revising ANDA Labeling**  
2/2/2022 *Federal Register* notice: FDA is making available a draft guidance entitled “Revising ANDA Labeling Following Revision of the RLD Labeling.” This guidance provides recommendations for updating ANDA labeling following revisions to the reference-listed drug (RLD) labeling, including information on how to identify RLD labeling updates and how to submit labeling updates. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-01-27/pdf/2022-01577.pdf?ref=fdaweb.com).

**Guide on ANDA Info Requests/Review Letters**  
2/1/2022 *Federal Register* notice: FDA is making available a final guidance entitled “Information Requests and Discipline Review Letters Under GDUFA.” The document explains how FDA will issue and use an information request and discipline review letter during the assessment of an original ANDA. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-01-27/pdf/2022-01605.pdf?ref=fdaweb.com).